Skip to content
Open in App
Actuate Therapeutics logo

Actuate Therapeutics

web2

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing experimental canc...

Symbol ยท ACTU
Company profile

About

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing experimental cancer treatments that inhibit glycogen synthase kinase-3, an enzyme involved in cell signaling and tumor growth. Its main drug candidate, elraglusib, is being studied for difficult-to-treat cancers and is intended to affect tumor survival pathways and immune responses. The company has tested an intravenous formulation in early and mid-stage clinical studies, including research involving pancreatic cancer and pediatric solid tumors. It is also developing an oral tablet formulation for further clinical evaluation. Actuate licenses the underlying compound from university research institutions and has not established commercial sales of an approved medicine.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ACTU
Expert coverage

Actuate Therapeutics profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment